NCT00389376 - Phase I Trial of Silymarin for Chronic Liver Diseases | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

January 31, 2008

Study Completion Date

February 29, 2008

Conditions

Hepatitis CNon-Alcoholic Fatty Liver Disease

Interventions

DRUG

Placebo

DRUG

Silymarin

140 mg every 8 hours

DRUG

Silymarin

280 mg single dose

DRUG

Silymarin

280 mg single dose + every 8 hours

DRUG

Silymarin

560 mg single dose + every 8 hours

DRUG

Silymarin

560 mg single dose + every 8 hours

DRUG

Silymarin

280 mg every 8 hours

DRUG

Silymarin

700 mg single dose + every 8 hours

Trial Locations (5)

15261

University of Pittsburgh, Graduate School of Public Health, Pittsburgh

19104

University of Pennsylvania, Philadelphia

19107

Thomas Jefferson University, Philadelphia

27599

The University of North Carolina at Chapel Hill, Chapel Hill

02215

Beth Israel Deaconess Medical Center, Boston

All Listed Sponsors

collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

National Center for Complementary and Integrative Health (NCCIH)

NIH